CTLA4 and non-small cell lung carcinoma: Immune checkpoint blockade via the inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death protein 1 (PD-1) receptors has shown recent success in the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma.